This is a Phase 1/2b trial for the treatment of patients with either advanced or refractory B cell Acute Lymphoblastic Leukemia or B-lineage lymphoblastic lymphoma.

The study compares 2 different experimental chemotherapy combinations with the usual chemotherapy combination given during post-Induction therapy.

This study is testing the safety and effectiveness of adding a targeted therapy (ruxolitinib) to standard chemotherapy for children, adolescents, and young adults with high-risk acute lymphoblastic leukemia with CRLF2 and other JAK pathway mutations.

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as WU-CART-007 (“study drug”). 

This clinical trial is adding the study drug, Carfilzomib, to a standard relapse chemotherapy regimen.

The overall goal of this study is to find the best strategies used by parents and patients for managing these symptoms when receiving maintenance therapy.

This purpose of this study is to determine the efficacy of humanized CD19 CAR  T cells (huCART19) in pediatric and young adult patients with high-risk relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19.

This study will determine the safety and usefulness of using the CliniMACS Prodigy platform to manufacture huCART19 cells.

CHOP, in collaboration with Dana-Farber Cancer Institute, is conducting a study for children, adolescents, and young adults up to 31 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drugs ribociclib and everolimus to a standard relapse chemotherapy regimen.